WO2005017185A3 - HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS - Google Patents

HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS Download PDF

Info

Publication number
WO2005017185A3
WO2005017185A3 PCT/US2004/022907 US2004022907W WO2005017185A3 WO 2005017185 A3 WO2005017185 A3 WO 2005017185A3 US 2004022907 W US2004022907 W US 2004022907W WO 2005017185 A3 WO2005017185 A3 WO 2005017185A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nuclear factor
hepatocyte nuclear
modulator compounds
hnf
Prior art date
Application number
PCT/US2004/022907
Other languages
French (fr)
Other versions
WO2005017185A2 (en
Inventor
Pierre Michellys
Jyun-Hung Chen
Christopher Mapes
Daniel Ruppar
Donald Karanewsky
Anthony Thompson
Original Assignee
Ligand Pharmceuticals Inc
Pierre Michellys
Jyun-Hung Chen
Christopher Mapes
Daniel Ruppar
Donald Karanewsky
Anthony Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmceuticals Inc, Pierre Michellys, Jyun-Hung Chen, Christopher Mapes, Daniel Ruppar, Donald Karanewsky, Anthony Thompson filed Critical Ligand Pharmceuticals Inc
Publication of WO2005017185A2 publication Critical patent/WO2005017185A2/en
Publication of WO2005017185A3 publication Critical patent/WO2005017185A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Abstract

The present invention is directed to hepatocyte nuclear factor 4α (HNF-4α) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds and pharmaceutical compositions for modulating HNF-4α receptors as well as processes mediated by HNF-4α receptors. Also provided are methods of making such compounds and pharmaceutical compositions, as well as intermediates used in their synthesis.
PCT/US2004/022907 2003-07-16 2004-07-16 HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS WO2005017185A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48823703P 2003-07-16 2003-07-16
US60/488,237 2003-07-16

Publications (2)

Publication Number Publication Date
WO2005017185A2 WO2005017185A2 (en) 2005-02-24
WO2005017185A3 true WO2005017185A3 (en) 2005-07-14

Family

ID=34193074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022907 WO2005017185A2 (en) 2003-07-16 2004-07-16 HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS

Country Status (1)

Country Link
WO (1) WO2005017185A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127264A2 (en) * 2009-04-30 2010-11-04 Burnham Institute For Medical Research HNF4α ANTAGONISTS AND METHODS OF USE
US20100317706A1 (en) * 2009-04-30 2010-12-16 Bumham Institute For Medical Research HNF4alpha MODULATORS AND METHODS OF USE
CN107250112B (en) * 2014-10-10 2021-04-23 高力研究有限公司 Fluorescent synthetic retinoids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US6391287B1 (en) * 1999-05-06 2002-05-21 L'oreal Composition containing at least one bicyclic aromatic compound and at least one lipophilic sunscreen, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US6391287B1 (en) * 1999-05-06 2002-05-21 L'oreal Composition containing at least one bicyclic aromatic compound and at least one lipophilic sunscreen, and uses thereof

Also Published As

Publication number Publication date
WO2005017185A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
NO20061845L (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2005089118A3 (en) Novel bicyclic compounds as modulators of androgen receptor function and method
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2003086306A3 (en) 5ht2c receptor modulators
MX2009005461A (en) N-oxides of 4,5-epoxy-morphinanium analogs.
WO2004108133A3 (en) Modulators of vr1 receptor
DK1730147T3 (en) Substituted 1,4,8-triazaspiro [4.5] decan-2-one compounds for the treatment of obesity
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
MX2011006132A (en) Fused imidazole carboxamides as trpv3 modulators.
WO2005018573A3 (en) 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2010073128A3 (en) Fused imidazole derivatives as trpv3 antagonist
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
NO20073369L (en) Modulators of muscarinic receptors
WO2009084034A3 (en) Chromane derivatives as trpv3 modulators
EA200700246A1 (en) TRICYCLIC DERIVATIVES OF PYRAZOL AS A MODULATOR OF A CANNABINOID RECEPTOR
MX2007007225A (en) Vitamin d receptor modulators.
IL183655A0 (en) Vitamin d receptor modulators
WO2005009104A3 (en) Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
WO2005017185A3 (en) HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS
UA104861C2 (en) Chromane derivatives as trpv3 modulators
WO2005010202A3 (en) PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
DE602004031245D1 (en) 1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase